Interactions between 4‐HPR and diet in NMU‐induced mammary tumorigenesis
- 1 January 1994
- journal article
- other
- Published by Taylor & Francis in Nutrition and Cancer
- Vol. 21 (3) , 271-283
- https://doi.org/10.1080/01635589409514325
Abstract
The present study was designed to determine whether the chemopreventive effect of the synthetic retinoid N(4‐hydroxyphenyl)retinamide (4‐HPR) on mammary tumorigenesis was influenced by diet. Three diets were used: the closed‐formula grain‐based Wayne Lab Blox, the open‐formula grain‐based NIH‐07, and the casein‐based semipurified AIN‐76A. Groups of 25 virgin female F‐344 rats were fed the experimental diets beginning one week before a single injection of N‐methyl‐N‐nitrosourea (NMU, 45 mg/kg body wt iv) at 50 days of age. The experimental design was as follows: Group 1, unsupplemented AIN‐76A; Group 2, AIN‐76A supplemented with 4‐HPR starting seven days before NMU until termination (—7) Group 3, AIN‐76A supplemented with 4‐HPR seven days after NMU until termination (+7) Group 4, Wayne (no 4‐HPR) Group 5, Wayne (4‐HPR, ‐7) Group 6, Wayne (4‐HPR, +7): Group 7, NIH‐07; Group 8, NIH‐07 (4‐HPR, ‐7). 4‐HPR [782 mg/kg diet (2 mM)] was given to all supplemented groups. Termination was 25 weeks post‐NMU. Analysis of tumor incidence, multiplicity, and latency indicated that 1) control rats fed the AIN‐76A diet exhibited significantly higher mammary tumor yields than rats fed unsupplemented natural‐ingredient diets (Wayne and NIH‐07) and 2) 4‐HPR inhibited mammary tumor development in the two grain‐based diets but enhanced tumor development in the AIN‐76A diet. Animals fed the AIN‐76A diet gained weight to a greater extent than those fed the Wayne or NIH‐07 diets and exhibited lower levels of circulating 4‐HPR.Keywords
This publication has 38 references indexed in Scilit:
- Long-term tolerability of fenretinide (4-HPR) in breast cancer patientsEuropean Journal of Cancer and Clinical Oncology, 1991
- Phase II study of Fenretinide (N-[4-Hydroxyphenyl]retinamide) in advanced breast cancer and melanomaInvestigational New Drugs, 1990
- A highly potent antiangiogenic activity of retinoidsCancer Letters, 1989
- Suppression of rat mammary cancer development by N-(4-hydroxy-phenyDretinamide (4-HPR) following surgical removal of first palpable tumorCarcinogenesis: Integrative Cancer Research, 1989
- Influence of some dietary chemopreventive agents on the expression of functional differentiation of the mouse mammary glandin vitroInternational Journal of Cancer, 1987
- Inhibition of rat mammary carcinogenesis by an arotinoid without a polar end group (Ro 15-0778)European Journal of Cancer and Clinical Oncology, 1987
- Influence of hormones on N-(4-hydroxyphenyl) retinamide inhibition of 7,12-dimethylbenz[a]anthracene transformation of mammary cells in organ cultureCancer Letters, 1982
- Inhibition of mammary and urinary bladder carcinogenesis by a retinoid and a maleic anhydride-divinyl ether copolymer (MVE-2)Carcinogenesis: Integrative Cancer Research, 1982
- Effect of short‐term administration of n‐(4‐hydroxyphenyl)‐all‐trans‐retinamide on chemically induced mammary tumorsNutrition and Cancer, 1982
- Retinoid prevents mammary gland transformation by carcinogenic hydrocarbon in whole-organ culture.Proceedings of the National Academy of Sciences, 1979